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Integrative organ crosstalk regulates key aspects of
energy homeostasis, and its dysregulation may
underlie metabolic disorders such as obesity and
diabetes. To test the hypothesis that crosstalk
between the liver and pancreatic islets modulates
b cell growth in response to insulin resistance, we
used the liver-specific insulin receptor knockout
(LIRKO) mouse, a unique model that exhibits
dramatic islet hyperplasia. Using complementary
in vivo parabiosis and transplantation assays, as
well as in vitro islet culture approaches, we demon-
strate that humoral, nonneural, non-cell-autonomous
factor(s) induces b cell proliferation in LIRKO mice.
Furthermore, we report that a hepatocyte-derived
factor(s) stimulates mouse and human b cell prolifer-
ation in ex vivo assays, independent of ambient
glucose and insulin levels. These data implicate the
liver as a critical source of b cell growth factor(s) in
insulin-resistant states.INTRODUCTION
Diabetes has reached epidemic proportions in both developed
and developing countries, and the cost of treating individuals
with complications resulting from uncontrolled hyperglycemia
is a major economic burden in the world. A promising but still
unrealized goal of efforts to improve diabetes therapy is the iden-
tification of novel factors that promote b cell regeneration, with
the long-term goal of increasing functional b cell mass in patients
with either type 1 or type 2 diabetes. Reduced functional b cellCmass is a central feature in both forms of the disease and in dia-
betes associated with obesity (Muoio and Newgard, 2008).
While autoimmune destruction of b cells is the major cause of
b cell loss in type 1 diabetes, a failure of b cells to compensate
for ambient insulin resistance leads to uncontrolled hypergly-
cemia in type 2 diabetes.
Lending encouragement to therapeutic strategies aimed at
enhancing b cell mass, decades of research indicate that b cells
possess the capacity to compensate for both physiological
(pregnancy) and pathological (obesity) insulin resistance (Ogilvie,
1933; Van Assche et al., 1978). Although b cell growth in both
humans and rodents has been documented to occur through
self-duplication of preexisting b cells (Dor et al., 2004; Meier
et al., 2008; Teta et al., 2007), albeit at low levels, the source of
putative growth factor(s) mediating this process, especially in
the context of insulin resistance, remains unknown. Among
possible systemic regulators of b cell mass, gut-derived incretins
such as glucagon-like peptide-1 (GLP-1), glucose-dependent
insulin-tropic polypeptide (GIP) (Renner et al., 2010; Saxena
et al., 2010), adipocyte-derived adipokines including leptin
(Morioka et al., 2007) and adiponectin (Holland et al., 2011),
muscle-derived myokines such as IL-6 (Ellingsgaard et al.,
2008; Suzuki et al., 2011), macrophage-derived cytokines
including IL-1b, IFNg, and TNF-a (Wang et al., 2010), bone-
derived osteocalcin (Ferron et al., 2008), thyroid-derived T3/T4
hormones (Jo¨rns et al., 2010; Verga Falzacappa et al., 2010),
platelet-derived growth factor (PDGF) (Chen et al., 2011),
serotonin (Kim et al., 2010), and FGF21 (Wente et al., 2006)
have each been implicated. However, the lack of significant
and consistent alterations in these known factors in the
peripheral blood that can fully account for the b cell prolifera-
tion in the insulin-resistant LIRKO mouse model (Table S1)
prompted us to explore the presence of an as yet uniden-
tified factor that is derived from an insulin-resistant liver. Toell Reports 3, 401–410, February 21, 2013 ª2013 The Authors 401
test the hypothesis that crosstalk between the liver and pan-
creatic islets, communicated via a systemic humoral factor,
mediates compensatory b cell regeneration in the LIRKOmouse,
we used in vivo (parabiosis, transplantation) and in vitro (pri-
mary islet b cell proliferation assay) models to identify blood-
borne and hepatocyte-produced soluble factors on b cell
proliferation.
RESULTS AND DISCUSSION
Concerted efforts in diabetes research are aimed at identifying
molecules that specifically promote b cell regeneration without
adverse proliferation of cells in other tissues. To determine
whether LIRKO mice, which manifest a dramatic hyperplasia
of the endocrine pancreas, exhibit increased proliferation in
extrapancreatic tissues, we injected bromodeoxyuridine (BrdU;
100 mg/kg body weight) intraperitoneally in 3-month-old LIRKO
mice and assessed proliferation of b cells, a cells, and cells in
metabolic organs such as the liver, adipose and skeletal muscle,
and in nonmetabolic tissues such as the lung, kidney, and
spleen. We observed a 2-fold increase in b cell mass (LIRKO
1.32 ± 0.2 versus control 0.68 ± 0.08mg; p < 0.05; n = 6) in LIRKO
mice compared to littermate controls that was due to enhanced
b cell proliferation evidenced by a 2.5-fold increase in BrdU
incorporation (LIRKO 1% ± 0.08% versus control 0.4% ±
0.07% BrdU+ b cells; p < 0.001; n = 6) and Ki67 staining (LIRKO
1.34% ± 0.1% versus control 0.51% ± 0.08% Ki67+ b cells; p <
0.001; n = 6) in the LIRKOs. TUNEL staining did not reveal signif-
icant differences in the number of apoptotic b cells between
groups. We also observed no difference in a cell proliferation
(LIRKO 0.24% ± 0.09% versus control 0.29% ± 0.1% BrdU+
a cells; n = 6) (Figures 1A–1F), or in the proliferation of cells in
multiple non-b cell tissues, including visceral adipose, subcuta-
neous adipose, muscle, kidney, liver, or spleen. Although we did
observe some increase in proliferating lung cells (LIRKO 0.7% ±
0.02% versus control 0.43% ± 0.08% BrdU+ cells; n = 6; p <
0.05) (Figures 1G and 1H), histological analyses of tissues
dissected from 12-month-old LIRKOs revealed no tumor-like
phenotypes (Figure S1; Table S2), and the life span of the
LIRKOs was similar to littermate controls. These data indicate
that LIRKO mice exhibit a robust b cell-specific proliferation in
response to insulin resistance.
Circulating Nonneuronal Nonautonomous Factors Drive
b Cell Replication in LIRKO Mice
To directly address whether b cell proliferation in the LIRKO
mouse is mediated by systemic factors, we first used a parabi-
osis model (Bunster and Meyer, 1933). Five to 6-week-old
male mice were surgically joined at the shoulder and hip girdles,
and successful anastomosis was confirmed within 2 weeks of
joining by Evans Blue Dye injection (data not shown). Animals
remained parabiosed for 16 weeks, and b cell replication was
subsequently assessed by BrdU incorporation (Figure 2A). Three
surgical models were generated: control/control, control/LIRKO,
and LIRKO/LIRKO. All parabiont groups grew normally, with
a weekly increase in their body weights, and the blood glucose
of the parabiont partners was within the normal range and did
not significantly differ between groups (Figures S2A–S2C). After402 Cell Reports 3, 401–410, February 21, 2013 ª2013 The Authors16 weeks of parabiosis, LIRKO and control parabionts displayed
similar fasting blood glucose levels and circulating insulin levels
and were higher in control partners joined with LIRKOs
compared to nonparabiosed controls and controls parabiosed
with controls (Figures S3A–S3D). As expected, BrdU incorpora-
tion revealed low b cell mitosis in control mice and a significant
elevation in LIRKO animals (control 0.03% ± 0.005% versus
LIRKO 0.14% ± 0.02% BrdU+ b cells; p < 0.005; n = 5–6).
We also noted a low level of b cell proliferation in the control
parabionts (Figures 2F and S4) compared to the single
controls (Figures 1C and 1D). We believe this may be secondary
to the parabiosis procedure itself and requires further investiga-
tion. BrdU incorporation was similar in pancreatic b cells of
same-genotype parabionts: low in control/control (0.03%
BrdU+ b cells; n = 5–6); and high in LIRKO/LIRKO (0.19%
BrdU+ b cells; n = 5–6). Interestingly, BrdU incorporation was
significantly increased in pancreatic b cells of control mice joined
with LIRKO mice (control in control/LIRKO parabionts 0.09% ±
0.01% versus control in control/control parabionts [0.03% ±
0.004% and 0.03% ± 0.008%] BrdU+ b cells; p < 0.01;
n = 5–6) (Figures 2B–2F). The latter observations were confirmed
by immunostaining for phospho-Histone H3 (pHH3) (Figure S4).
These data indicate the presence of cell nonautonomous,
circulating factors produced in LIRKO mice that promote b cell
replication. Previous studies have implicated neural pathways
in modulating b cell proliferation in a cell-nonautonomous
fashion (Imai et al., 2008). To evaluate a possible influence of
such neural effects on b cell proliferation in the LIRKO model,
we undertook transplantation studies to assess b cell replication.
A total of 125 size-matched islets freshly isolated from either
control or LIRKO mice were transplanted under the kidney
capsule of either control or LIRKO recipients. To minimize
systematic error, each recipient mouse (control or LIRKO) was
transplanted with two islet grafts, one derived from control and
the other derived from LIRKO donors, under the left and right
kidney, respectively (Figure 2G). Sixteen weeks after transplan-
tation, islet grafts were harvested, sectioned, and analyzed
for b cell BrdU incorporation. As expected, control islets
grafted into control animals exhibited minimal b cell proliferation
(0.017% ± 0.017% BrdU+ b cells). Intriguingly, the same
donor-derived control islets showed an 8-fold increase in
b cell replication when transplanted instead into LIRKO recipi-
ents (0.139% ± 0.03%BrdU+ b cells; p < 0.05; n = 3–5). Notably,
LIRKO islets transplanted into LIRKO recipients exhibited robust
b cell replication, reminiscent of the increased b cell proliferation
seen in the pancreas of unmanipulated LIRKO mice, whereas
this response was blunted when LIRKO islets were grafted
instead into control animals (Figure 2H). Taken together, these
two complementary experimental strategies provide evidence
that circulating nonneural and non-cell-autonomous factors
contribute to expanding b cell mass in response to insulin
resistance.
LIRKO Serum Induces Selective b Cell Replication
In Vivo
We next sought to evaluate the relative importance of blood-
borne molecules versus cells in the induction of b cell prolifera-
tion in the LIRKO model. Five to 6-week-old male mice were
Figure 1. Selective b Cell Proliferation in LIRKO Mice
Three to 4-month-old LIRKO and control mice were intraperitoneally injected with BrdU (100mg/kg body weight) 5 hr before animals were sacrificed, and tissues
were dissected, fixed and stained as indicated.
(A) Pancreatic sections immunostained for insulin/BrdU/DAPI, insulin/Ki67/DAPI, insulin/TUNEL, or glucagon/BrdU/DAPI as indicated.
(B) b Cell mass quantification.
(C and D) Quantification of BrdU+ insulin+ and Ki67+ insulin+ cells: between 2,000 and 5,000 insulin+ cells per animal were counted in control versus LIRKO
pancreases, respectively.
(E) Quantification of TUNEL+ insulin+ cells: between 2,000 and 5,000 insulin+ cells/mouse were counted in control versus LIRKO pancreases, respectively.
(F) Quantification of BrdU+ glucagon+ cells: between 2,000 and 5,000 insulin+ cells/mouse were counted in control versus LIRKO pancreases, respectively.
(G) Quantification of nuclei BrdU+ in indicated tissues: 4,000–5,000 cells/mouse were counted in each of liver, kidney, spleen, and lung, and 1,500 cells/mouse
were counted in each for visceral (Visc.) and subcutaneous (Sc.) adipose tissue and skeletal muscle (Sk).
(H) Representative images of proliferating cells in tissue sections stained with BrdU.
Data represent mean ± SEM. *p% 0.05 and ***p% 0.001 (n = 6 in each group). See also Figure S1 and Table S2.injected intraperitoneally with freshly isolated serum from
6-month-old control or LIRKO mice, respectively, twice a day
(150 ml per injection) on days 1, 3, and 5. The recipients were
injected with BrdU (100 mg/kg body weight) once a day on
days 2, 4, and 6. The pancreases were harvested on day 6 to
assess b and a cell replication (Figure 3A). Control mice injected
with LIRKO serum (LIRKO(s)) displayed an 2-fold increase in
their endogenous b cell, but not a cell, replication compared to
littermates injected with control serum (control(s)) (Figures
3B–3E). We saw no significant difference in the number of
TUNEL+ b cells (Figures 3F and 3G) between LIRKO(s) and
control(s)-injected groups. Assessment of BrdU incorporation
in extrapancreatic tissues, including liver, subcutaneousCadipose, muscle, kidney, spleen, and lung, revealed no signifi-
cant differences in proliferation between groups, whereas
a mild decrease was observed in visceral adipose (Figure 3H).
This in vivo study confirms that a circulating molecule(s), stable
in serum, selectively promotes b cell proliferation in the LIRKO
model.
LIRKO Serum Increases Mouse and Human Islet b Cell
Replication In Vitro
To gain further insight into the mode of action of this circulating
b cell growth factor, we next established an in vitro functional
assay to directly assess the impact of LIRKO or control serum
on b cell replication in isolated mouse islets. We cultured isletsell Reports 3, 401–410, February 21, 2013 ª2013 The Authors 403
Figure 2. Circulating Nonneuronal Nonautonomous Factors Drive b Cell Replication in LIRKO Mouse
(A) Schematic of the parabiosis experiment. See also Figures S2, S3, and S4.
(B–E) Single and parabiont models were intraperitoneally injected with BrdU (100 mg/kg body weight) 5 hr before animals were sacrificed, and pancreases were
dissected and immunostained for insulin, BrdU, and DAPI.
(F) Quantification of BrdU+ insulin+ cells: three sections separated by 80 mm were analyzed, and between 2,000 and 10,000 cells were counted in each group
(n = 5–6 in each parabionts group).
(G) Schematic of the transplantation experiment.
(H) Quantification of BrdU+ insulin+ cells in islet grafts as indicated: three to six islet graft sections were analyzed and counted between 2,000 and 10,000 cells in
each group (n = 3–5 in each group).
Data represent mean ± SEM. *p% 0.05.in media containing serum from LIRKO or control mice and then
assessed b cell proliferation using Ki67 immunostaining and
fluorescence microscopy. Randomly selected Ki67+ b cells in
each of the groups in all experiments were confirmed by
confocal microscopy (Figure 4A). We first tested the ability of
6-month-old LIRKO serum to stimulate b cell proliferation and
found that a 1:10 dilution of serum derived from LIRKO mice
increased b cell proliferation in primary islets at 24 and 48 hr (Fig-
ure S5). LIRKO serum from 3-month-old mice also enhanced
b cell proliferation in mouse islets (LIRKO(s) 1.58% ± 0.3%404 Cell Reports 3, 401–410, February 21, 2013 ª2013 The Authorsversus control(s) 0.52% ± 0.1% Ki67+ b cells; p < 0.05; n = 6).
Moreover, mouse islets cultured in 12-month-old LIRKO serum
showed a greater number of replicating b cells compared to
islets incubated with age-matched control serum (LIRKO(s)
1.3% ± 0.5% versus control(s) 0.7% ± 0.2% Ki67+ b cells;
p = 0.3; n = 4–6) (Figures 4B and 4C); this increase lost its statis-
tical significance probably due to an elevated insulin resistance
in aging controls that itself contributed to b cell proliferation
(Kulkarni et al., 2003; Mori et al., 2010). TUNEL staining showed
no significant difference in b cell apoptosis in islets cultured in
Figure 3. LIRKO Serum Induces Selective b Cell Replication In Vivo
Five to 6-week-old mice were injected intraperitoneally twice daily with 150 ml serum derived from 6-month-old control or LIRKO mice on days 1, 3, and 5. BrdU
was injected intraperitoneally (100mg/kg body weight) on days 2, 4, and 6. Animals were sacrificed 5 hr before the last BrdU injection, and tissues were dissected
for immunostaining studies.
(A) Schematic of the experimental design.
(B andC) Representative images and quantification of BrdU+ insulin+ cells: two sections separated by 80 mmwere analyzed, and at least 4,000 insulin+ cells were
counted for each animal.
(D and E) Representative images and quantification of BrdU+ glucagon+ cells: 400–600 glucagon+ cells were counted in each animal.
(F and G) Representative images and quantification of TUNEL+ insulin+ cells: at least 2,000 insulin+ cells were counted in each animal.
(H) Representative images and quantification of nuclei BrdU+ in indicated tissues: for each animal, 4,000–5,000 cells were counted in sections from liver, kidney,
spleen, and lung, and 1,500 cells were counted in sections from visceral (Visc.) and subcutaneous (Sc.) adipose tissue and skeletal muscle.
Data represent mean ± SEM. *p% 0.05 (n = 3 in each group).LIRKO(s) versus control(s) (Figure 4D). Preliminary data indicate
that the ability of the LIRKO serum to stimulate b cell proliferation
is reduced when subjected to heat inactivation, suggesting
that the putative circulating factor may be a protein (data not
shown). To examine whether the proliferating effect of LIRKO
serum is conserved across species, we next cultured human
islets from nine healthy and two diabetic donors (for donor
characteristics, see Table S3) in serum isolated from 12- to
18-month-old male LIRKO or control mice. Similar to the effects
onmouse b cells, serum from LIRKOmice enhanced human islet
b cell proliferation, albeit at a level lower than that reported in
a recent study by Rieck et al. (2012). Importantly, LIRKO serumCwas also effective in promoting proliferation of islet b cells from
patients with type 2 diabetes (Figures 4E–4G). Thus, the b cell
mitogen(s) present in the circulation of LIRKO mice shows
conserved activity toward mouse and human islets, including
islets from patients with type 2 diabetes. Glucose and insulin
have been reported to promote b cell growth (Assmann
et al., 2009a, 2009b; Bonner-Weir et al., 1989) and are potential
candidates in the LIRKOmodel, whichmanifests glucose intoler-
ance and hyperinsulinemia (Michael et al., 2000). However, our
observations suggest that glucose is not a dominant factor in
the LIRKO mouse for several reasons. First, control mice para-
biosed to LIRKOs for 16 weeks demonstrate up to a 7-foldell Reports 3, 401–410, February 21, 2013 ª2013 The Authors 405
Figure 4. LIRKO Serum Increases Mouse and Human Islet b Cell Replication In Vitro
Five to 6-week-old mouse islets were stimulated with control or LIRKO serum for 48 hr. Islets were embedded in agarose and used for immunostaining studies.
Culture media were assayed for glucose and insulin. WT, wild-type.
(A) Schematic of the experimental protocol. See also Figures S5 and S6.
(B) Representative images of mouse islets stimulated with sera derived from 3-month-old (upper panel) and 12-month-old animals (lower panel).
(C) Quantification of Ki67+ insulin+ cells in (B): two sets of three serial sections separated by 80 mmwere analyzed. At least 4,000–5,000 cells were counted in each
experimental group (n = 5 in each group).
(D) Quantification of TUNEL+ insulin+ cells in (B): at least 3,000–4,000 cells were counted in each group (n = 5 in each group).
(E and F) Representative images of healthy and type 2 diabetic donor islets stimulated with control versus LIRKO serum for 24 hr. See also Table S3.
(G) Quantification of Ki67+ insulin+ cells in (E) and (F): three sets of three serial sections separated by 80 mm were analyzed. At least 3,000–4,000 cells were
counted in each group. See also Table S3.
Data represent mean ± SEM. *p% 0.05. (See Serum Stimulation and Human Islet Studies sections in Experimental Procedures.)increase in proliferation despite normal blood glucose levels
(120 mg/dl) during the parabiosis period (Figures S2A
and S2C). Second, serum used to examine the effects on b cell
proliferation (see Figure 4A) was derived from either normoglyce-
mic 3-month-old or hypoglycemic 12-month-old animals
(data not shown). Finally, to further exclude a role for glucose,
we cultured islets in a constant concentration of 5.5 mM
glucose in experiments with serum from LIRKO or control mice
(serum:culture media at 1:10 dilution) and observed an increase
in proliferation in b cells only in the former group. Furthermore,
the glucose levels in culture media at the beginning and at the406 Cell Reports 3, 401–410, February 21, 2013 ª2013 The Authorsend of islet incubation were similar in both groups (Fig-
ure S6A). We believe that insulin may be permissive but unlikely
to account for the high level of b cell proliferation in our
model because the levels of insulin in the diluted serum (Fig-
ure S6B) used in in vitro studies (see Figure 4) are significantly
lower compared to the levels found in the circulation in
LIRKO mice (11.63 ± 2.4 ng/ml [3-month-old LIRKOs] versus
2.59 ± 1 ng/ml [diluted serum in culture media] and 17.8 ±
4.4 ng/ml [12-month-old LIRKOs] versus 1.4 ± 1.3 ng/ml [diluted
serum in culture media]) (Table S1; Michael et al., 2000).
Together, these data support the presence of a glucose- and
insulin-independent liver-derived factor that promotes the
expansion of b cell mass.
Hepatocyte-Derived Factors Stimulate Mouse and
Human Islet b Cell Replication In Vitro
The common embryonic origin of the liver and the pancreas
(Zaret, 2008) coupledwith the robust b cell proliferation response
to tissue-specific insulin resistance in the liver compared to the
virtual lack of a compensatory response when insulin resistance
was restricted to muscle (Bru¨ning et al., 1998), adipose (Blu¨her
et al., 2002), or brain (Bru¨ning et al., 2000) prompted us to
hypothesize that the liver serves as a source of b cell growth
factor(s) in response to metabolic insults such as insulin resis-
tance. To test this hypothesis, we collected conditioned media
from liver explant cultures (LECM) from either 3- or 12-month-
old LIRKO or control animals and evaluated their effects on
b cell proliferation in mouse islets (Figure 5A). Ki67-positive
b cells were significantly elevated in islets cultured in LECM
from either 3- or 12- month-old LIRKO mice, compared to cells
cultured in LECMderived fromage-matched controls (Figure 5B).
Interestingly, whereas mouse islets cultured in control LECM
derived from 3- and 12-month-old animals displayed similar
levels of proliferation, the levels were 2-fold higher in cultures
containing 12-month-old LIRKO-LECM compared to 3-month-
old control LECM (Figure 5C). This age-dependent effect of
LIRKO-LECM is consistent with the age-dependent increase in
b cell proliferation in LIRKO mice (Okada et al., 2007). Similarly,
b cells in islets obtained from healthy human controls and
patients with type 2 diabetes (for donor characteristics, see
Table S3) cultured in LECM derived from LIRKO animals ex-
hibited increased proliferation compared to islets from the
same donors cultured in control LECM (Figures 5D and 5E).
The liver contains multiple cell types, including hepatocytes,
Kupffer cells, and endothelial cells (Si-Tayeb et al., 2010). To
determine whether the growth factor activity in LIRKO serum
is a product of hepatocytes or nonhepatic cells, we used
conditioned media from cultures of primary hepatocytes
(HCM), isolated from control or LIRKO mice in an in vitro b cell
proliferation assay. Primary mouse islets cultured in LIRKO
HCMexhibited markedly increased b cell proliferation compared
to islets stimulated with control HCM (control HCM, 0.13% ±
0.03% versus LIRKO HCM, 0.64% ± 0.12%; p < 0.05; n = 5).
The number of TUNEL+ b cells was similar in both conditions
(Figures 5F and 5G). Furthermore, the proliferative effect of
LIRKO HCM was also evident when human islets obtained
from a patient with type 2 diabetes (for donor characteristics,
see Table S3) were exposed to LIRKOHCM compared to control
HCM (Figures 5H and 5I). Thus, insulin-resistant hepatocytes
produce a b cell growth-promoting factor(s) that enhances
proliferation of mouse and human b cells.
Although numerous signaling pathways impacting b cell
growth have been documented (Kulkarni et al., 2012), specific
blood-borne molecules that trigger b cell replication directly in
response to insulin resistance have, to our knowledge, not
been reported. The absence of a consistent increase in one or
more growth factors in the serum of the LIRKOs (Table S1)
supports the notion that additional unidentified factors are
necessary to promote the full magnitude of proliferationCobserved in the LIRKOmodel. In summary, we provide evidence
that a conserved systemic hepatocyte-derived growth factor(s)
promotes b cell proliferation inmouse and human islets, support-
ing a liver-to-pancreas axis in the adaptive b cell growth
response to insulin resistance.
EXPERIMENTAL PROCEDURES
Animals
Mice were housed in pathogen-free facilities and maintained on a 12 hr light/
dark cycle in the Animal Care Facility at Joslin Diabetes Center, Boston, and
the Foster Biomedical Research Laboratory, Brandeis University, Waltham,
MA. All studies conducted and protocols used were approved by the Institu-
tional Animal Care and Use Committee of the Joslin Diabetes Center and Bran-
deis University and were in accordance with NIH guidelines. LIRKOmice were
generated by crossing Albumin-Cre to IRflox/flox on a mixed genetic back-
ground and were backcrossed for more than 15 generations on the C57/Bl6
background. LIRKO mice (Albumin-Cre+/,IRflox/flox) and their littermate Lox
controls (Albumin-Cre/,IRflox/flox) were genotyped as described previously
by Okada et al. (2007). Blood glucose was monitored using an automated
glucose monitor (Glucometer Elite; Bayer), and plasma insulin was detected
by ELISA (Crystal Chem).
Parabiosis
Parabiosis surgery was performed as described earlier by Eggan et al. (2006).
Cross-circulation was determined 2 weeks after surgery by Evans Blue trans-
mission (Pietramaggiori et al., 2009). Body weight and blood glucose of para-
biont animals were monitored weekly. After a 16 week parabiosis period,
animals were sacrificed, and pancreases were collected for morphometric
analysis.
Islet Isolation and Transplantation
Islets were isolated from 9-month-old mice using the intraductal collagenase
technique (Kulkarni et al., 1999). Islets were handpicked, concentrated in
a pellet, and kept on ice until transplantation (Flier et al., 2001). Surgery was
performed in mice after intraperitoneal injection (15 ml/g body weight) of
a 1:1 (w/v) mixture of 2,2,2-tribromoethanol and tert-amyl alcohol and diluted
1:50 with PBS (pH 7.4). The capsules of the kidneys were incised, and the islets
were implanted near the upper pole of each kidney in 5-month-old male mice.
The capsules were cauterized, and the mice were allowed to recover on
a heating pad.
Growth Factors and Hormones Assays
ELISA-based assays were used to measure growth factors and hormones,
including IGF-1 (catalog #MG100; R&D Systems), HGF (catalog #ab100686;
Abcam), EGF (catalog #IB39411; IBL-America), PDGFAA (catalog #DAA00B;
R&D Systems), PDGFBB (catalog #MBB00; R&D Systems), VEGF (Millipore),
FGF21 (catalog #EZRMFGF21-26K; Millipore), Gastrin (catalog #E91224mu;
USCN Life Science), Adiponectin (catalog #EZMADP-60K; Millipore),
Ostepontin (catalog #MOST00; R&D Systems), and Osteocalcin (catalog
#EIA4010; International). Multiplex-based assays were used tomeasure endo-
crine hormones (catalog #MENDO-75; Millipore), gut hormones (catalog
#MGT-78K; Millipore), adipokines (catalog #MADPK-71K; Millipore), and
Cytokines/Chemokines (catalog #MPXMCYTO-70K.lxt; Millipore).
Serum Stimulation
Sera were obtained after coagulated blood was centrifuged twice for 15 min at
8,000 rpm at 4C and stored at80C until use. Pancreatic islets were isolated
from 5-week-old male mice by liberase and thermolysin digestion (Roche),
handpicked, and cultured for 16 hr in RPMI 1640 with 7 mM glucose and
10% FBS (v/v). A total of 150 size-matched mouse islets were starved in
RPMI 1640 with 0.1% BSA (v/v) containing 3 mM glucose for 3 hr and there-
after treated with RPMI 1640 with 5.5 mM glucose supplemented every
12 hr with 10% (v/v) serum obtained from 3- or 12-month-old LIRKO and
control mice. Twenty-four to 48 hr later, islets were handpicked, fixed with
4% paraformaldehyde, embedded in agarose/paraffin, and sectioned forell Reports 3, 401–410, February 21, 2013 ª2013 The Authors 407
Figure 5. Hepatocyte-Derived Factors Stimulate Mouse and Human Islet b Cell Replication In Vitro
Five to 6-week-old mouse islets were stimulated for 24 hr with LECM or HCM obtained from control or LIRKO mice. Islets were embedded in agarose and
subsequently analyzed by immunostaining. Culture media were assayed for glucose and insulin.
(A) Schematic of the experimental protocol. See also Figure S6.
(B) Representative images of mouse islets stimulated with LECM derived from 3-month-old (upper panel) and 12-month-old animals (lower panel).
(C) Quantification of Ki67+ insulin+ cells (upper panel) and TUNEL+ insulin+ cells (lower panel): at least 3,000–5,000 cells were counted in each experimental
group (n = 5 in each group).
(D) Representative images of healthy human donor islets (upper panel) and type 2 diabetic donor islets (lower panel) treated for 24 hr with LECM derived from
control versus LIRKO mice. See also Table S3.
(E) Quantification of Ki67+ insulin+ cells in (D): between 3,000 and 4,000 cells were counted in each condition (Control LECM versus LIRKO LECM) in control islets,
and at least 2,000 cells were counted in each experimental group for type 2 diabetic islets. See also Table S3.
(F) Representative images of mouse islets stimulated with HCM derived from 6-month-old control versus LIRKO mice or fibroblast-conditioned media (FCM).
(G) Quantification of Ki67+ insulin+ cells (upper panel) and TUNEL+ insulin+ cells (lower panel): between 4,000 and 5,000 cells were counted in each experimental
group (Control HCM versus LIRKO HCM) (n = 5 in each group).
(H) Representative images of type 2 diabetic donor islets stimulated with control or LIRKO HCM. See also Table S3.
(I) Quantification of Ki67+ insulin+ cells in (H): at least 2,000 cells were counted in each experimental condition. See also Table S3.
Data represent mean ± SEM. *p% 0.05. (See LECM Stimulation, HCM Stimulation, and Human Islet Studies sections in Experimental Procedures.)immunohistochemistry studies. To evaluate b cell replication, sections were
analyzed by fluorescent microscopy subsequent to Ki67, TUNEL, and insulin
immunostaining.
LECM Stimulation
Liver explant-conditioned medium preparation was adapted from Nicoleau
et al. (2009). Mice were anesthetized with Avertin (240mg/kg intraperitoneally),408 Cell Reports 3, 401–410, February 21, 2013 ª2013 The Authorsand 100 mg liver explants were dissected from LIRKO or control mice.
Explants were washed twice in cold PBS, incubated in PBS at 37C for
30 min, and then cultured in serum-free Dulbecco’s modified Eagle’s medium
(DMEM) containing 5.5 mM glucose. After a 3 day incubation, LECM were
collected, centrifuged, and kept at 80C till use. Islets were initially starved
for 3 hr in DMEM containing 3 mM glucose and 0.1% BSA and thereafter stim-
ulated for 24 hr with DMEM/5.5 mM glucose media containing 10% LECM.
Islet b cell proliferation and apoptosis were analyzed by fluorescent micros-
copy after Ki67, TUNEL, and insulin immunostaining.
HCM Stimulation
Hepatocytes were isolated from 6-month-old LIRKO and controlmice by colla-
genase digestion via portal vein perfusion (Sun et al., 2005). Mice were anes-
thetized with Avertin (240 mg/kg intraperitoneally), and the portal vein was
cannulated with JELCO 22G 3 1 inch catheter (Smiths Medical). The liver
was perfused with EGTA solution (5.4 mmol/l KCl, 0.44 mmol/l KH2PO4,
140 mmol/l NaCl, 0.34 mmol/l Na2HPO4, and 0.5 mmol/l EGTA [pH 7.4]) and
digested with DMEM containing 0.075% type I collagenase. Hepatocytes
were washed twice in Hepatocyte Wash Medium (Invitrogen). The isolated
mouse hepatocytes were seeded in collagen-coated 6-well plates (BD
BioCoat) at a density of 106 cells/well in DMEM containing 25 mM glucose
and 10% FBS (v/v). Sixteen hours later, hepatocytes were cultured for
24 hr in serum-free DMEM containing 5.5 mM glucose. HCM was collected,
centrifuged, and kept at 80C. Islets were initially starved for 3 hr in DMEM
containing 3 mM glucose and 0.1% BSA and thereafter incubated for 24 hr
in DMEM/5.5 mMglucosemedia containing 50%HCM. Islet b cell proliferation
and apoptosis were analyzed by fluorescent microscopy after Ki67, TUNEL,
and insulin immunostaining.
Human Islet Studies
Human islets were obtained from the Integrated Islet Distribution Program. All
studies and protocols used were approved by the Joslin Diabetes Center’s
Committee on Human Studies (CHS#5-05). Upon arrival, islets were cultured
overnight in Miami Media #1A (Cellgro). The islets were then starved in
Final Wash/Culture Media (Cellgro) for 3 hr prior to stimulation with serum
(diluted to 10% v/v), LECM (diluted to 10% v/v), or HCM (diluted to 50% v/v)
for 24 hr.
Immunostaining Studies
Pancreases and islets were analyzed by immunostaining using anti-Ki67 (BD),
anti-insulin (Abcam), or anti-glucagon (Sigma-Aldrich) antibodies.
Counting Proliferating b Cells
In all experiments, cell counting was manually performed in a blinded fashion
by a single observer. BrdU+ or Ki67+ b cells were assessed by immuno-
fluorescence microscopy. Insulin+ cells showing nuclear DAPI staining were
considered as b cells. Insulin+ cells showing nuclear colocalized staining for
DAPI+ and Ki67+ (or BrdU+) were counted as proliferating b cells. The
double-positive cells (Ins+/BrdU+ or Ins+/Ki67+) were confirmed in randomly
selected cells in all experiments by confocal microscopy.
BrdU Injection Studies
Mice were injected with BrdU intraperitoneally (100 mg/kg body weight) 5 hr
prior to animal sacrifice for immunostaining of the pancreas. BrdU injections
in the in vivo serum administration experiments were performed on three occa-
sions as denoted in Figure 2A.
Statistical Analysis
All data are presented asmean ±SEMand analyzed using unpaired, two-tailed
Student’s t test. A p value of less than 0.05 is considered significant.
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